Pricing for Oncology Biosimilars—Reply
In Reply I thank Drs Jensen and Tichy for the opportunity to respond to the comments on our article on hospital adoption and pricing for oncology biosimilars. Their comments are factually correct and add insight into the complex process of drug payment and strengthen the core message of our article.
We haven't written up this one. JAMA has the full story — the link below goes straight to it.